Stacy & Asia
Member Since 2017
Forgive me if this isn't the right place to post this, but I wanted to see what others have heard about this insulin. It looks promising, could be a longer acting once a day insulin and sounds to be more even keel than Lantus and Levermir with potentially less incidents of hypo. This article is older and it wasn't approved in the U.S. yet when it was written. It now is available in the U.S. Anyone heard of any studies or veterinary use of it yet? I found a couple brief mentions of it being used in cats in other countries, but nothing of substance in those articles other than it was indeed prescribed for cats.
"Insulin degludec (Tresiba, Novo Nordisk) is a new-generation, ultra-long-acting basal insulin analogue. This latest insulin analogue differs from other long-acting insulin preparations in having a longer half-life, flat time-action profile (less likely to cause hypoglycemia) and less day-to-day variability (less glycemic variability).19-21
Degludec is a neutral, soluble ultra-long-acting insulin that forms large soluble multihexamers at the subcutaneous injection site. Its molecular structure is similar to the human insulin amino acid sequence, apart from deletion of Threonine at position B30 and the addition of a 16-carbon fatty diacid attached to Lysine at position B29 via a glutamic acid spacer.
After SC administration, degludec results in the formation of a subcutaneous depot of soluble multihexamers that results in the slow release of insulin monomers into the systemic circulation. Insulin degludec has an onset of action of 30-90 minutes (similar to insulin glargine and insulin detemir). There is no peak in activity, due to the slow release into systemic circulation. The duration of action of insulin degludec is over 42 hours, unlike the 18 to 26 hours provided by current marketed long-acting insulins such as glargine and detemir. The large molecular size of the degludec multihexamers allows for continuous slow release of insulin with less pharmacodynamic variability and within-subject variability than is seen with the currently available insulin analogs.19-21
In studies in people with type 1 and type 2 diabetes, degludec was demonstrated to provide similar improvements in blood glucose control as glargine or detemir while also reducing the rate of overall and nocturnal hypoglycemia. One study found that degludec’s long duration of action makes it possible to dose the drug at different times each day (i.e., in the morning one day, the evening the next day, the morning the day after that) without sacrificing effectiveness and safety."
Here's a link to the original article, if anyone is interested. It discusses all types of insulin:
https://www.researchgate.net/profil...roblem-diabetic.pdf?origin=publication_detail
"Insulin degludec (Tresiba, Novo Nordisk) is a new-generation, ultra-long-acting basal insulin analogue. This latest insulin analogue differs from other long-acting insulin preparations in having a longer half-life, flat time-action profile (less likely to cause hypoglycemia) and less day-to-day variability (less glycemic variability).19-21
Degludec is a neutral, soluble ultra-long-acting insulin that forms large soluble multihexamers at the subcutaneous injection site. Its molecular structure is similar to the human insulin amino acid sequence, apart from deletion of Threonine at position B30 and the addition of a 16-carbon fatty diacid attached to Lysine at position B29 via a glutamic acid spacer.
After SC administration, degludec results in the formation of a subcutaneous depot of soluble multihexamers that results in the slow release of insulin monomers into the systemic circulation. Insulin degludec has an onset of action of 30-90 minutes (similar to insulin glargine and insulin detemir). There is no peak in activity, due to the slow release into systemic circulation. The duration of action of insulin degludec is over 42 hours, unlike the 18 to 26 hours provided by current marketed long-acting insulins such as glargine and detemir. The large molecular size of the degludec multihexamers allows for continuous slow release of insulin with less pharmacodynamic variability and within-subject variability than is seen with the currently available insulin analogs.19-21
In studies in people with type 1 and type 2 diabetes, degludec was demonstrated to provide similar improvements in blood glucose control as glargine or detemir while also reducing the rate of overall and nocturnal hypoglycemia. One study found that degludec’s long duration of action makes it possible to dose the drug at different times each day (i.e., in the morning one day, the evening the next day, the morning the day after that) without sacrificing effectiveness and safety."
Here's a link to the original article, if anyone is interested. It discusses all types of insulin:
https://www.researchgate.net/profil...roblem-diabetic.pdf?origin=publication_detail